CD44 and neoplasm: As shown in the tumor growth graphs in Fig.3A, compared with scr control, the weekly measurements of CD44 and CD147 KD xenografts, treated either with vehicle control (VC) or DTX (25 mg/kg), showed a significantly reduced tumor growth rate in both VC (P<0.05) and DTX-treated groups (P<0.05) (on the left and middle panels).